Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

PolyNovo (ASX:PNV) share price up 30% in two weeks… What’s going on?

Medical device manufacturer PolyNovo Ltd (ASX: PNV) has had an impressive run recently, with its share price up nearly 30% in just two weeks.

A positive announcement yesterday gave Polynovo’s share price an additional 5% boost.

PolyNovo’s flagship product NovoSorb BTM is used for serious burns victims and helps regenerate human tissue where it has been severely damaged.

PNV share price

Source: Rask Media ASX PNV 2-year share price chart

PolyNovo signs new purchasing agreement

It was revealed yesterday, PolyNovo has signed a group purchasing agreement with a US group purchasing organisation (GPO) called Premier Inc.

Under the agreement which is effective from April 1, PolyNovo will be able to access Premier member hospitals and their representatives who are responsible for introducing new technology to members.

PolyNovo’s marketing and consulting teams will provide training and support for the Premier team in order for them to effectively adopt the BTM product.

PolyNovo’s sales team can now enter hospitals that were previously restricted, with the procurement process also streamlined to enhance the adoption process.

Premier services has over 2,000 acute care hospitals including 100 designated trauma centres. It also has 63 children’s hospitals including 20 designated as trauma/burn centres.

Management commentary

Managing Director Paul Brennan said: “This signing with Premier, the second largest GPO in the US, is a major milestone. We have recently signed with Aptitude and First Choice. These GPO agreements put our disruptive BTM on a much larger list of hospitals than our sales team can get around in the short term.

We will continue expanding our sales team into new markets to support hospitals and surgeons but now also to match the geographical footprint of the GPOs. We look forward to demonstrating improved health economic benefits for Premier hospital members and their patients.”

Why have PolyNovo’s shares been rocketing recently?

If you look back to December last year, you might remember that PolyNovo’s shares took quite a steep dive after rallying hard for the prior four or so months.

The sentiment can change extremely quickly with companies like these and perhaps the market believed shares were oversold around the $2.50 mark.

An additional catalyst that coincided with this most recent rally was some insider buying action.

Chairman David Williams has bought two lots of shares in the past couple of weeks and has increased his holdings by 400,000 shares.

Are PolyNovo’s shares a buy?

PolyNovo’s HY21 results highlighted the company’s sales efforts were being affected by COVID-19 as they had limited access to hospitals and surgeons.

Management didn’t give any guidance due to the ongoing nature of COVID-19, but they did say they’re expecting lumpy sales in the second half of the year.

PolyNovo’s ongoing focus will be its pivotal trial of BTM, the development of a new pipeline of products, and the continued expansion into new geographic regions.

The company’s results were fairly underwhelming, and I think it highlights how long it can take for growth stories such as this to evolve. I’d like to be a shareholder of PolyNovo, but they’re a hold for the time being.

If you’re interested in other ASX growth shares, I’d recommend signing up for a free Rask account to get access to our stock reports.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report — or get it emailed to you — for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content